M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Pharmaceutical TechnologyRegeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.Read full story pharminent May 19, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs. Read full story Post navigation Previous: SCOTUS won’t hear pharma’s IRA complaintsNext: VERTANICAL’s VER-01 gains FDA breakthrough status for low back pain Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
